Desmopressin intranasal - CPX Pharmaceuticals/Serenity Pharmaceuticals

Drug Profile

Desmopressin intranasal - CPX Pharmaceuticals/Serenity Pharmaceuticals

Alternative Names: Desmopressin acetate; Intranasal desmopressin - Serenity Pharmaceuticals; Noctiva; SER 120

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CPEX Pharmaceuticals; Serenity Pharmaceuticals Corporation
  • Developer Serenity Pharmaceuticals Corporation
  • Class Antidiuretics; Antihaemorrhagics; Hormones; Urologics; Vasoconstrictors; Vasopressins
  • Mechanism of Action Vasopressin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Nocturia

Most Recent Events

  • 05 Oct 2017 Avadel Pharmaceuticals intends to launch desmopressin intranasal in the second quarter of 2018
  • 05 Oct 2017 Efficacy data from the subset analysis of the phase III trials in Nocturia released Avadel Pharmaceuticals
  • 05 Sep 2017 Serenity Pharmaceuticals and Avadel Pharmaceuticals enter a licensing agreement to develop and commercialise Desmopressin intranasal in USA and Canada
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top